2026-10-19T01:08:40Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/169872026-10-18T20:41:11Zopenairedrivercom_ebyu_10000col_ebyu_10001Biochemical and Histopathologic Investigation of the Effect of Rilmenidine on Ovarian Ischemia-Reperfusion Injury in RatsYilmaz, Betul KalkanBulut, SevalYilmaz, NesrinYucel, NurinisaCicek, BetulKadioglu, Berrin GoktugBakan, NuriMendil, Ali SefaSuleyman, HalisRilmenidineischemia-reperfusionovarian damageantioxidantanti-inflammatoryOXIDATIVE STRESSISCHEMIA/REPERFUSION INJURYSUPEROXIDE-DISMUTASETISSUEINFLAMMATIONCATALASETORSIONDAMAGEPharmacology & PharmacyBackground and Objective: Rilmenidine is an antihypertensive drug with sympatholytic properties as well as antioxidative and anti-inflammatory properties. To investigate the biochemical and histopathological effects of Rilmenidine on Ovarian IschemiaReperfusion (I/R) injury in a rat model, this study aims to determine its potential protective role against oxidative stress and tissue damage associated with ovarian IR injury. Materials and Methods: The 24 albino Wistar female rats were divided into four groups: Healthy (HG), sham-operation (SOG),ovarian ischemia-reperfusion (OIRG) and Rilmenidine+ovarian ischemia-reperfusion (ROIRG). Ovaries in SOG, OIRG and ROIRG groups were exposed to ischemia for three hrs, followed by reperfusion for 6 days. The ROIRG rats were treated with Rilmenidine (0.2 mg/kg) daily for 6 days before ischemia. The ovaries were analyzed for oxidant, antioxidant and proinflammatory cytokines and examined histopathologically. Statistical analysis was performed using one-way ANOVA and Kruskal-Wallis tests (p<0.05). Results: The IR procedure increased tissue malondialdehyde, tumor necrosis factor-a, interleukin-6 and interleukin-1$ levels and decreased total glutathione, superoxide dismutase and catalase levels (p<0.001). Severe histopathologic damage and 8-hydroxy-20deoxyguanosine immunopositivity were also observed in ovarian tissues ofOIRG (p<0.001). Rilmenidine inhibited IR-related biochemical, histopathological and immunohistochemical abnormalities (p<0.05). Conclusion: Rilmenidine may be an efficient therapeutic strategy for the protection from ovarian IR injury.ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET2025Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/16987https://doi.org/10.3923/ijp.2025.181.1881811-7775enINTERNATIONAL JOURNAL OF PHARMACOLOGYinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/16987